Home › Calculator › XNCR Dividend Calculator 2026
XNCR Dividend DRIP Calculator 2026
8.63% YieldHealthcareXencor, Inc. · NASDAQ
Price: $23.18 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When XNCR pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your XNCR snowball 📈
$10,000 in XNCR → $22.5K in 10 years · $898.63/month
About Xencor, Inc. (XNCR) — Dividend Analysis 2026
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
Compare XNCR with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full XNCR DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open XNCR position with:
🌍 XNCR Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold XNCR.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 8.63% | 5.83% | $863 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 7.34% | 4.54% | $734 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 6.90% | 4.10% | $690 / yr |
| 🇬🇧 UK ISA | 0% | 8.63% | 5.83% | $863 / yr |
| 🇬🇧 UK Taxable | 8.75% | 7.87% | 5.07% | $787 / yr |
| 🇨🇦 TFSA | 0% | 8.63% | 5.83% | $863 / yr |
| 🇨🇦 CA Taxable | 25% | 6.47% | 3.67% | $647 / yr |
| 🇦🇺 Super (pension) | 15% | 7.34% | 4.54% | $734 / yr |
| 🇦🇺 AU Taxable | 30% | 6.04% | 3.24% | $604 / yr |
| 🇩🇪 DE Taxable | 26.375% | 6.35% | 3.55% | $635 / yr |
| 🇫🇷 FR Taxable | 30% | 6.04% | 3.24% | $604 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 XNCR Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 XNCR Dividend Payment Schedule
XNCR pays quarterly — 4 times per year. Next ex-div: TBD.
📊 XNCR vs Healthcare Benchmarks
How XNCR compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for XNCR sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ XNCR Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-16 | 10,302 | — | — | ||
| A-Award | 2026-06-16 | 20,604 | $12.20 | $251.4K | ||
| A-Award | 2026-06-16 | 10,302 | — | — | ||
| A-Award | 2026-06-16 | 20,604 | $12.20 | $251.4K | ||
| A-Award | 2026-06-16 | 10,302 | — | — | ||
| A-Award | 2026-06-16 | 20,604 | $12.20 | $251.4K | ||
| A-Award | 2026-06-16 | 10,302 | — | — | ||
| A-Award | 2026-06-16 | 20,604 | $12.20 | $251.4K | ||
| A-Award | 2026-06-16 | 10,302 | — | — | ||
| A-Award | 2026-06-16 | 20,604 | $12.20 | $251.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where XNCR earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the XNCR dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Xencor, Inc. (XNCR) is currently trading at $23.18, 52% below its 52-week high. The current dividend yield is 8.63% based on an annual payout of $2.00 per share.
XNCR (Xencor, Inc.) — 8.63% Dividend Yield Analysis
Xencor, Inc. (XNCR) is a healthcare stock currently trading at $23.18 with a dividend yield of 8.63%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (8.63%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.